Skip Navigation LinksHome > November 2009 - Volume 28 - Issue 11 > Kawasaki Disease After Vaccination: Reports to the Vaccine A...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3181a66471
Original Studies

Kawasaki Disease After Vaccination: Reports to the Vaccine Adverse Event Reporting System 1990–2007

Hua, Wei MD, PhD*; Izurieta, Hector S. MD, MPH*; Slade, Barbara MD†; Belay, Ermias D. MD‡; Haber, Penina MPH†; Tiernan, Rosemary MD, MPH§; Woo, Emily Jane MD, MPH*; Iskander, John MD, MPH†; Braun, M Miles MD, MPH*; Ball, Robert MD, MPH, ScM*

Supplemental Author Material
Collapse Box

Abstract

Background: Kawasaki disease (KD) is a multisystemic vasculitis primarily affecting children <5 years. A review of RotaTeq (rotavirus vaccine live) clinical trial data revealed higher, though not statistically significantly, KD rates among RotaTeq vaccines than placebo recipients. In June 2007, the RotaTeq label was revised accordingly.

Objectives: To describe and assess KD reported to Vaccine Adverse Event Reporting System (VAERS) for all US licensed vaccines.

Methods: We reviewed all KD reports received by VAERS from 1990 through mid-October 2007. Cases were characterized by age, gender, onset interval, and vaccine type. Proportional reporting ratio (PRR) was used to evaluate KD reporting for each vaccine compared with all others. Reporting rates were calculated using number of doses distributed as denominator.

Results: Through October14, 2007, 107 KD reports were received by VAERS: 26 were categorized as classic cases, 19 atypical, 52 possible, and 10 were noncases. Of the 97 cases, 91% were children <5 years. There was no clustering of onset intervals after day 1 postvaccination. Before the RotaTeq label revision, the KD PRR was elevated only for Pediarix (DTaP, hepB, and IPV combined) but the KD reporting rate for Pediarix (0.59/100,000 person-years) was much lower than the background incidence rate (9–19/100,000 person-years) for children <5 years in the United States. After the revision, reporting of KD for RotaTeq was stimulated but the reporting rate for RotaTeq (1.47/100,000 person-years) was still much lower than the background rate.

Conclusions: Our review does not suggest an elevated KD risk for RotaTeq or other vaccines. Continued postmarketing monitoring for KD is ongoing.

© 2009 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.